First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma ; volume:150 ; number:6 ; day:18 ; month:6 ; year:2024 ; pages:1-11 ; date:6.2024
Journal of cancer research and clinical oncology ; 150, Heft 6 (18.6.2024), 1-11, 6.2024

Creator: Lin, Yan-Song
Li, Shuo
Yang, Xia
Guo, Rong-Ping
Huang, Yu-Hua
Bai, Kun-Hao
Weng, Jun
Yun, Jing-Ping

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00432-024-05795-2

URN: urn:nbn:de:101:1-2409262128057.153193723983

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lin, Yan-Song
Li, Shuo
Yang, Xia
Guo, Rong-Ping
Huang, Yu-Hua
Bai, Kun-Hao
Weng, Jun
Yun, Jing-Ping
SpringerLink (Online service)

Other Objects (12)

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Graffiti | Streetart

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Graffiti | Streetart

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Graffiti | Streetart

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

"PDL

Bestimmung der PD-L1-Expression auf CTCs von NSCLC-Patienten und Korrelation mit dem Therapieansprechen auf PD-(L)1-Inhibitoren

PDL kompakt

PDL kompakt

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Related objects

Reset password